IL17A and psoriasis: This study delineated that IκBζ may be a better target than TNFα or IL‐17A to manage psoriasis, as psoriasis‐like skin inflammation was still occurring in the absence of TNFα and IL‐17A, whereas it was completely missing in the absence of IκBζ.18